Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-08

Clinical Trial Update: Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating DNN.65.21.005 for benign prostatic hyperplasia is planned, with the study currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DNN.65.21.005

Snippet

Sponsor: Ache Laboratorios Farmaceuticos S.A. | Conditions: Prostatic Hyperplasia, Benign | Phase 3 | Status: NOT_YET_RECRUITING